Commensal flora triggered target anti-inflammation of alginate-curcumin micelle for ulcerative colitis treatment

Background Vedolizumab has been shown to induce clinical remission in patients with active ulcerative colitis. Treatment with anti-integrin vedolizumab leads to clinical remission in 16.9% and clinical response in 47.1% of cases after 6 weeks. However, in clinical practice, no decision to discontinue or continue vedolizumab therapy is made until 14 weeks at the earliest. Objective The aim of this study is to develop an algorithm for optimizing vedolizumab administration in patients with moderate-to-severe ulcerative colitis by calculating the probability of clinical response at week 14, on the basis of the data from week 6. Methods This is a prospective, single-arm, multicentric, noninterventional, observational study with no interim analyses and a sample size of 35 evaluable patients. Results The enrollment started in August 2018 and was still open at the date of submission. The study is expected to complete in September 2020. Conclusions The early identification of patients who are responding to an integrin antibody is therapeutically beneficial. At the same time, patients who are not responding can be identified earlier. The development of a therapeutic algorithm for identifying patients as responders or nonresponders can thus help prescribing physicians avoid ineffective treatments and stop these very early.

Download Full-text

Ulcerative colitis - treatment with biologicals

Revista da Associação Médica Brasileira ◽

10.1590/1806-9282.65.4.547 ◽

2019 ◽

Vol 65 (4) ◽

pp. 547-553

Author(s):

Fabio Vieira Teixeira ◽

Eduardo Garcia Vilela ◽

Aderson Omar Mourão Cintra Damião ◽

Andrea Vieira ◽

Idblan Carvalho De Albuquerque ◽

...

Keyword(s):

Ulcerative Colitis ◽

Ulcerative Colitis Treatment

Download Full-text

Effects of a β-type glycosidic polysaccharide from Flammulina velutipes on anti-inflammation and gut microbiota modulation in colitis mice

Food & Function ◽

10.1039/c9fo03017d ◽

2020 ◽

Vol 11 (5) ◽

pp. 4259-4274

Author(s):

Ruiqiu Zhao ◽

Yang Ji ◽

Xin Chen ◽

Anxiang Su ◽

Gaoxing Ma ◽

...

Keyword(s):

Ulcerative Colitis ◽

Gut Microbiota ◽

Sodium Sulfate ◽

Dextran Sodium Sulfate ◽

Flammulina Velutipes ◽

Anti Inflammation

Using the Flammulina velutipes polysaccharide (FVP) extracted from our previous study, herein, we investigated the improvement of this β-type glycosidic polysaccharide in alleviating dextran sodium sulfate-induced ulcerative colitis (UC) in mice.

Download Full-text

Use of Synbiotics for Ulcerative Colitis Treatment

Current Clinical Pharmacology ◽

10.2174/1574884715666191226120322 ◽

2020 ◽

Vol 15 (3) ◽

pp. 174-182 ◽

Cited By ~ 3

Author(s):

Marianna Roselli ◽

Alberto Finamore

Keyword(s):

Ulcerative Colitis ◽

Gastrointestinal Tract ◽

Intestinal Microbiota ◽

Strong Impact ◽

Beneficial Effects ◽

System A ◽

Bowel Diseases ◽

Ulcerative Colitis Treatment ◽

Inflammatory Bowel

Inflammatory bowel diseases, namely Crohn's disease and ulcerative colitis, are currently considered multifactorial pathologies in which various combined environmental factors act on genetic background, giving rise to chronic inflammation of the gastrointestinal tract. Ulcerative colitis is an inflammation of the colon caused by a dysregulated immune response to host intestinal microbiota in genetically susceptible subjects. Ulcerative colitis has a strong impact on patients' quality of life, as well as high costs for the health-care system. A great interest on the role of intestinal microbiota modulation in ulcerative colitis is emerging. Several studies have shown an improvement of inflammatory markers and symptoms in ulcerative colitis patients through treatments with probiotics and prebiotics separately. Despite the low number of studies on the treatment of ulcerative colitis by specific strains of probiotics plus selected prebiotics, i.e. synbiotics, the results are promising, even if discordant. The mechanism of action in synbiotics supplementation is still unclear and needs more investigation, although there is a large number of data indicating that the synergism between probiotics and prebiotics favours the survival and implantation of probiotics into the gastrointestinal tract with beneficial effects on human health by modulating the inflammatory response and gut microbiota composition. The aim of this minireview is to describe the main in vitro, animal and human studies performed up to now, that have used synbiotics to treat ulcerative colitis, and to highlight limitations and future perspectives.

Download Full-text